속보"우리는 연간 30번의 베팅을 하지 않는다": 비제이 판데가 a16z에서 40억 달러를 투자한 후 소액 베팅에 대해 말한다

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.